Engrail Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$157M
- Investors
-
14
Engrail Therapeutics General Information
Description
Developer of transformative medicines designed to reduce the enormous burden of diseases that impact the nervous system. The company's medicines aid in transforming the lives of patients with life-limiting diseases of the nervous system and unite biological insights with clinical data to build and catalyze a diversified portfolio of transformative medicines and get simplified therapies for complex diseases, enabling patients to reduce overall disease burden.
Contact Information
Website
www.engrail.comCorporate Office
- 12750 High Bluff Drive
- Suite 190
- San Diego, CA 92130
- United States
Corporate Office
- 12750 High Bluff Drive
- Suite 190
- San Diego, CA 92130
- United States
Engrail Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series B) | 14-Mar-2024 | $157M | Completed | Clinical Trials - Phase 2 | ||
| 1. Early Stage VC (Series A) | 03-Aug-2021 | Completed | Clinical Trials - Phase 1 |
Engrail Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-2C | ||||||||
| Series A-2B | ||||||||
| Series A-2A | ||||||||
| Series A-1C | ||||||||
| Series A-1B | ||||||||
| Series A-1A | 8,277,270 | $0.000100 | 8% | $1.1 | $1.1 | 1x | $1.1 | 3.51% |
| Series A | 6,085,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 2.58% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Engrail Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Engrail Therapeutics Patents
Engrail Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026122971-A1 | Deuterated organic compound and uses thereof | Pending | 06-Dec-2024 | ||
| WO-2026122986-A1 | Deuterated organic compounds and uses thereof | Pending | 06-Dec-2024 | ||
| WO-2026122968-A1 | Heterocyclic compounds and uses thereof | Pending | 06-Dec-2024 | ||
| WO-2026122972-A1 | Organic compounds and uses thereof | Pending | 06-Dec-2024 | ||
| WO-2026050276-A1 | Gaba a receptor modulator antiseizure treatments | Pending | 26-Aug-2024 | A61P25/08 |
Engrail Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Engrail Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aberdeen Investments (Scotland) | Asset Manager | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority | ||
| F-Prime | Venture Capital | Minority |
Engrail Therapeutics Acquisitions (1)
Engrail Therapeutics’s most recent deal was a Merger/Acquisition with NeuroCycle Therapeutics. The deal was made on 02-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NeuroCycle Therapeutics | 02-Feb-2021 | Merger/Acquisition | Drug Discovery |
Engrail Therapeutics FAQs
-
When was Engrail Therapeutics founded?
Engrail Therapeutics was founded in 2019.
-
Where is Engrail Therapeutics headquartered?
Engrail Therapeutics is headquartered in San Diego, CA.
-
What is the size of Engrail Therapeutics?
Engrail Therapeutics has 34 total employees.
-
What industry is Engrail Therapeutics in?
Engrail Therapeutics’s primary industry is Drug Discovery.
-
Is Engrail Therapeutics a private or public company?
Engrail Therapeutics is a Private company.
-
What is the current valuation of Engrail Therapeutics?
The current valuation of Engrail Therapeutics is .
-
What is Engrail Therapeutics’s current revenue?
The current revenue for Engrail Therapeutics is .
-
How much funding has Engrail Therapeutics raised over time?
Engrail Therapeutics has raised $221M.
-
Who are Engrail Therapeutics’s investors?
Aberdeen Investments (Scotland), Eight Roads, Forbion, Foresite Capital, and F-Prime are 5 of 14 investors who have invested in Engrail Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
